Adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2025.
Discharge from liability for the Companys directors with respect to the performance of their duties during the fiscal year ended December 31, 2025.
Instruction to Deloitte Accountants B.V. as the Companys external auditor of the Companys Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2026.
Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the audit committee of the Companys Board of Directors.
Re-appointment of non-executive director of the Company until the annual general meeting 2030: John W. Smither
Re-appointment of non-executive director of the Company until the annual general meeting 2030: Janneke van der Kamp
Extension of authorization for the Board of Directors to issue ordinary shares (or rights to subscribe for ordinary shares) in the Companys capital.
Extension of authorization for the Board of Directors to limit or exclude pre-emption rights.
Approval of the NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan.
Non-binding, advisory vote to approve the 2025 compensation of named executive officers.